...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: AGM - Jan 7, 2016 - Details

I realize both companies were always potentially on the selling block but does it strike you as though the sale of RVX has been somewhat ramped up(or both?)?

Thanks

Share
New Message
Please login to post a reply